- Home
- XRTX vs PRFX Comparison
XRTX vs PRFX Comparison
Compare XRTX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XRTX
- PRFX
- Stock Information
- Founded
- XRTX 2011
- PRFX 2007
- Country
- XRTX Canada
- PRFX Israel
- Employees
- XRTX N/A
- PRFX N/A
- Industry
- XRTX Pharmaceuticals and Biotechnology
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- XRTX Health Care
- PRFX Health Care
- Exchange
- XRTX Nasdaq
- PRFX Nasdaq
- Market Cap
- XRTX 3.0M
- PRFX 3.0M
- IPO Year
- XRTX N/A
- PRFX 2020
- Fundamental
- Price
- XRTX $0.82
- PRFX $3.16
- Analyst Decision
- XRTX
- PRFX Hold
- Analyst Count
- XRTX 0
- PRFX 1
- Target Price
- XRTX N/A
- PRFX N/A
- AVG Volume (30 Days)
- XRTX 45.7K
- PRFX 3.2M
- Earning Date
- XRTX 11-15-2024
- PRFX 01-01-0001
- Dividend Yield
- XRTX N/A
- PRFX N/A
- EPS Growth
- XRTX N/A
- PRFX N/A
- EPS
- XRTX N/A
- PRFX N/A
- Revenue
- XRTX N/A
- PRFX N/A
- Revenue This Year
- XRTX N/A
- PRFX N/A
- Revenue Next Year
- XRTX N/A
- PRFX N/A
- P/E Ratio
- XRTX N/A
- PRFX N/A
- Revenue Growth
- XRTX N/A
- PRFX N/A
- 52 Week Low
- XRTX $0.82
- PRFX $0.43
- 52 Week High
- XRTX $7.00
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- XRTX 34.99
- PRFX 49.34
- Support Level
- XRTX $0.87
- PRFX $3.22
- Resistance Level
- XRTX $0.97
- PRFX $5.47
- Average True Range (ATR)
- XRTX 0.07
- PRFX 0.34
- MACD
- XRTX 0.00
- PRFX 0.04
- Stochastic Oscillator
- XRTX 0.00
- PRFX 15.97
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.